Fig. 3

Systemic administration of AL002a improves learning and memory and lowers amyloid deposition in 5XFAD mice. Panel a shows the radial-arm water maze data. Blocks 1–5 are day 1, and blocks 6–10 are day 2. The black line is the learning curve of the 5XFAD mice receiving AL002a, the gray line is the learning curve of the 5XFAD mice receiving control antibody, and the dashed line is the learning curve of the non-transgenic littermates receiving control or AL002a (data was pooled due to lack of difference between the two treatment groups). Panel b shows a bar graph to illustrate the difference in number of errors made for the final block of trials (block 10). Panel c shows the bar graph for the novel object recognition data, where % exploration time with novel object is shown. Fifty percent of the exploration time would represent chance. Panel d shows anti-mouse IgG immunohistochemistry from the frontal cortex and hippocampus of mice receiving either control or AL002a antibodies, magnification = ×200, scale bar = 25 μm. Panel e shows the total Aβ deposition in the hippocampus (images shown) and frontal cortex of control antibody or AL002a. Panel f shows Congo red labeling of compact amyloid deposits in the hippocampus (images shown) and frontal cortex of control antibody or AL002a. Panel g shows the biochemical assessment of soluble and insoluble beta-amyloid 38, 40, and 42 in the frontal cortex as measured using the Meso-Scale Discoveries multiplex ELISA. For all graphs, black bars are AL002a, and gray bars are control antibody. *P < 0.05, ** P < 0.01. For images in e and f, magnification = ×40, scale bars shown = 120 μm